2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI:10.1080/14737140.2024.2370382

Viria Beccia, Daniela Arduini, Roberto Iacovelli, Alessandro Scala, Denis Occhipinti, Chiara Ligato, Luigi Roca, Pierluigi Russo, Nazario Foschi, Giampaolo Tortora, Chiara Ciccarese

{"title":"2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.","authors":"Viria Beccia, Daniela Arduini, Roberto Iacovelli, Alessandro Scala, Denis Occhipinti, Chiara Ligato, Luigi Roca, Pierluigi Russo, Nazario Foschi, Giampaolo Tortora, Chiara Ciccarese","doi":"10.1080/14737140.2024.2370382","DOIUrl":null,"url":null,"abstract":"<p><p>In this article, we report the breakthrough acquisitions for renal cell carcinoma (RCC) management presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. The results from Keynote 564 showed an impressive overall survival (OS) advantage for pembrolizumab, in patients at higher risk of relapse after surgery and confirmed the benefit in terms of disease-free survival (DFS). Until now, pembrolizumab is the only immune checkpoint inhibitor (ICI) to prove a survival advantage. On the contrary, the results from CheckMate 914 trial showed the lack of benefit of adjuvant nivolumab. In the metastatic setting, the longer-term follow-up data of the CheckMate 9ER and CheckMate 214 trials reassessed the undoubtable role of ICI-based combination in first-line treatment, with a clear survival advantage in the subgroup of patients at intermediate/poor IMDC prognosis. No OS advantage was seen in favorable IMDC risk group patients. This 2024 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized therapy for RCC patients.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"657-660"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2370382","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In this article, we report the breakthrough acquisitions for renal cell carcinoma (RCC) management presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. The results from Keynote 564 showed an impressive overall survival (OS) advantage for pembrolizumab, in patients at higher risk of relapse after surgery and confirmed the benefit in terms of disease-free survival (DFS). Until now, pembrolizumab is the only immune checkpoint inhibitor (ICI) to prove a survival advantage. On the contrary, the results from CheckMate 914 trial showed the lack of benefit of adjuvant nivolumab. In the metastatic setting, the longer-term follow-up data of the CheckMate 9ER and CheckMate 214 trials reassessed the undoubtable role of ICI-based combination in first-line treatment, with a clear survival advantage in the subgroup of patients at intermediate/poor IMDC prognosis. No OS advantage was seen in favorable IMDC risk group patients. This 2024 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized therapy for RCC patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2024 年 ASCO 泌尿生殖系统癌症研讨会：聚焦肾细胞癌。

在这篇文章中，我们报告了 2024 年美国临床肿瘤学会（ASCO）泌尿生殖系统癌症研讨会上公布的肾细胞癌（RCC）治疗突破性成果。主题演讲 564 的结果显示，在术后复发风险较高的患者中，pembrolizumab 具有令人印象深刻的总生存期（OS）优势，并证实了其在无病生存期（DFS）方面的益处。迄今为止，pembrolizumab 是唯一证明具有生存优势的免疫检查点抑制剂（ICI）。相反，CheckMate 914 试验的结果表明，nivolumab 的辅助治疗效果不佳。在转移性环境中，CheckMate 9ER和CheckMate 214试验的长期随访数据再次评估了基于ICI的联合疗法在一线治疗中毋庸置疑的作用，在IMDC预后中等/较差的亚组患者中具有明显的生存优势。这次 2024 年 ASCO 泌尿生殖系统癌症研讨会为进一步发展 RCC 患者个性化治疗所需的知识奠定了基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.